Anti-Biopharmaceutical Immunization: prediction
and analysis of clinical relevance to minimize the RISK
WP1: "ADA assay development and validation and cohort management"
WP1 team leaders: | |
Medizinische Universität Innsbruck | Florian Deisenhammer |
UCB Pharma S.A. | Louis Christodoulou |
GlaxoSmithKline Research & Development Limited | Mary Birchler |
WP2: "Cellular characterization and mechanisms of the AD immune response"
WP2 team leaders: | |
University College London | Claudia Mauri |
Pfizer Limited | Tim Hickling |
Sanofi-Aventis Research and Development | Vincent Mikol |
WP3: "Evaluation and development of technologies for predicting immunogenicity"
WP3 team leaders: | |
Commissariat a L'Energie Atomique et aux Energies Alternatives | Bernard Maillère |
Novartis Pharma AG | Sebastian Spindeldreher |
Novo Nordisk A/S | Christian Ross Pedersen |
WP4: "Establishment of a data base, data analyses and integration"
WP4 team leaders: | |
Institut National de la Santé et de la Recherche Médicale | Philippe Broet |
SciCross AB | Pierre Dönnes |
Sanofi-Aventis Research and Development | Agnes Hincelin-Mery |
WP5: "Project management and communication"
WP5 team leaders: | |
Novartis Pharma AG | Sebastian Spindeldreher |
Institut National de la Santé et de la Recherche Médicale | Marc Pallardy |
GlaxoSmithKline Research & Development Limited | Steven Etheridge |
Institut National de la Santé et de la Recherche Médicale | Sophie Tourdot |
ALTA - Ricerca e Sviluppo in Biotecnologie S.r.l.u. | Riccardo Bertini |